Dr. Ross A Abrams
Claim this profileStudies Pancreatic Cancer
Studies Ovarian cysts
1 reported clinical trial
5 drugs studied
Area of expertise
1Pancreatic Cancer
CD4 positive
Viral Load negative
2Ovarian Cysts
CD4 positive
Viral Load negative
More about Ross A Abrams
Clinical Trial Related14 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments Ross A Abrams has experience with
- 3-Dimensional Conformal Radiation Therapy
- Capecitabine
- Erlotinib Hydrochloride
- Gemcitabine Hydrochloride
- Intensity-Modulated Radiation Therapy
Breakdown of trials Ross A Abrams has run
Pancreatic Cancer
Ovarian cysts
Stomach Cancer
Pancreatic Neoplasm
Pancreatic Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ross A Abrams specialize in?
Ross A Abrams focuses on Pancreatic Cancer and Ovarian cysts. In particular, much of their work with Pancreatic Cancer has involved CD4 positive patients, or patients who are Viral Load negative.
Is Ross A Abrams currently recruiting for clinical trials?
No, Ross A Abrams is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Ross A Abrams has studied deeply?
Yes, Ross A Abrams has studied treatments such as 3-Dimensional Conformal Radiation Therapy, Capecitabine, Erlotinib Hydrochloride.
What is the best way to schedule an appointment with Ross A Abrams?
Apply for one of the trials that Ross A Abrams is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.